Disease relevance of AIDS Dementia Complex
Psychiatry related information on AIDS Dementia Complex
High impact information on AIDS Dementia Complex
Chemical compound and disease context of AIDS Dementia Complex
Biological context of AIDS Dementia Complex
Anatomical context of AIDS Dementia Complex
Gene context of AIDS Dementia Complex
Analytical, diagnostic and therapeutic context of AIDS Dementia Complex
AIDS Dementia Complex
Maimone, D. et al., Brew, B.J. et al., Boven, L.A. et al., Lee, P.L. et al., Brunetti, A. et al., et al.
Boven, Gomes, Hery, Gray, Verhoef, Portegies, Tardieu, Nottet, Sporer, Koedel, Popp, Paul, Pfister, Chang, Ernst, Leonido-Yee, Witt, Speck, Walot, Miller, Boven, Middel, Portegies, Verhoef, Jansen, Nottet, Haughey, Cutler, Tamara, McArthur, Vargas, Pardo, Turchan, Nath, Mattson,
A possible contributor to AIDS-related dementia complex is the HIV envelope glycoprotein gp120, which damages neurons via a complex glutamate receptor- and calcium-dependent cascade [1].
The regional expression of immune-mediated and neurotoxic events in the human immunodeficiency virus (HIV)-infected brain in relationship to the acquired immunodeficiency syndrome (AIDS) dementia complex (ADC) and brain pathology remains uncertain [2].
After treatment of AIDS dementia complex with zidovudine and treatment of the opportunistic infections with specific antimicrobial therapies, CSF levels of quinolinic acid decreased in parallel with clinical neurological improvement [3].
Increased peroxynitrite activity in AIDS dementia complex: implications for the neuropathogenesis of HIV-1 infection [4].
Increased CSF TGF-beta levels were also detected in patients with other central nervous system (CNS) diseases: malignancies and AIDS dementia complex [5].
RESULTS: In 14 of 16 patients who tolerated HAART, CD4 count increased by 133+/-101 cells/mm3 (p = 0.0003), HIV Dementia Scale score increased by 1.8+/-2.4 points (p = 0.02), and AIDS dementia complex (ADC) stage decreased by 0.54+/-0.54 points (p = 0.003) [6].
Changes in neuropsychological test results were correlated with changes in serum concentration of neopterin irrespective of ZDV treatment, suggesting that monocyte/macrophage activation may be involved in the pathogenesis of HIV-encephalopathy [7].
Decrease of serum antioxidant capacity in patients with anorexia nervosa and Aids-encephalopathy are probably due primarily to malnutrition and secondly to insufficient antioxidant and immune system [8].
Cobalamin/folate deficiency, a significant feature in senile dementia of Alzheimer type and in AIDS-related dementia complex, will result in concomitant slowed synthesis of DNA and SAM [9].
Regions of sequence homology between gp120 and NLK may account for this inhibitory property of gp120 and functional interactions between gp120 and NLK may be important in the pathogenesis of the AIDS dementia complex [10].
Antiretroviral drugs other than zidovudine might be useful in the prevention of AIDS dementia complex [11].
AIDS dementia complex and didanosine [12].
Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia [13].
In the patients with AIDS dementia complex, CSF neopterin concentrations correlated with severity of disease and decreased in conjunction with clinical improvement following treatment with zidovudine [14].
These results suggest that CSF neopterin, although not disease-specific, may be useful as a surrogate marker for the presence of AIDS dementia complex and its response to antiviral therapy [14].
Expression of two cytokines and two key enzymes that are indicative of the presence of reactive oxygen intermediates and peroxynitrite was investigated in brain tissue of AIDS patients with and without AIDS dementia complex and HIV-seronegative controls [4].
This glycoprotein has been identified as a potent stimulator of monokines such as TNF-alpha and IL-6, which have been implicated as potential mediators of HIV-encephalopathy [15].
OBJECTIVES: To determine the efficacy of the non-nucleoside reverse transcriptase inhibitor atevirdine in the treatment of AIDS dementia complex (ADC) [16].
Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy [17].
OBJECTIVES: To determine the occurrence and cellular localization of inducible nitric oxide synthase (iNOS), NOS activity and its association with cell death in brains of AIDS and AIDS dementia complex (ADC) patients [18].
In previous studies, using polymerase chain reaction amplification of HIV-1 genes directly from pathologic tissues of children who died with AIDS encephalopathy, we showed that the reading frame of the HIV-1 regulatory nef gene is open, suggesting that the nef protein was expressed [19].
Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex [20].
NFkappaB activation, TNF-alpha expression, and apoptosis in the AIDS-Dementia-Complex [21].
We sought to determine whether the neurotoxin quinolinic acid (QUIN) was produced by macrophages or lymphocytes infected with isolates of HIV-1 with varying degrees of macrophage tropism derived from patients with varying stages of AIDS dementia complex (ADC) [22].
In addition, cerebral macrophages in patients with HIV-encephalopathy were strongly positive for endothelin [15].
OBJECTIVE: Concentrations of quinolinic acid, an N-methyl-D-aspartate agonist, are often elevated for long periods of time in the cerebrospinal fluid (CSF) and brain tissue of patients with AIDS dementia complex (ADC) [23].
PURPOSE: To demonstrate the technical feasibility and reliability of a multi-center study characterizing regional levels of the brain metabolite ratios choline (Cho)/creatine (Cr) and myoinositol (MI)/Cr, markers of glial cell activity, and N-acetyl aspartate (NAA)/Cr, a marker of mature neurons, in subjects with AIDS dementia complex (ADC) [24].
Only individual patients with severe AIDS dementia complex had increased levels of uPA (but not PAI-1) which fell upon initiation of antiretroviral therapy [25].
The cellular and regional expression of this chemokine and its relationship to the AIDS dementia complex (ADC), however, have remained undetermined [26].
Overexpression of nerve growth factor and basic fibroblast growth factor in AIDS dementia complex [27].
For example, concentration of TNF-alpha is increased in brain tissue of individuals who died with AIDS and correlates with the severity of AIDS Dementia Complex (ADC) [28].
Although our data indicate that intrathecal anti-MBP IgG may occur early during HIV-1 infection and that they are more common in patients with HIV-1-associated cognitive/motor complex, the possible demyelinating role of these antibodies remains to be demonstrated [29].
Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group [30].
By contrast, a significant elevation in compounds containing choline was present in patients in the early stages of HIV infection of who had CD4 counts greater than 200/microliter, in patients with normal MRI scans, and in all AIDS dementia complex groups, including subjects with no or minimal cognitive impairment [31].
Brain glucose metabolism was evaluated in four patients with acquired immunodeficiency syndrome (AIDS) dementia complex using [18F]fluorodeoxyglucose (FDG) and positron emission tomography (PET) scans at the beginning of therapy with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine), and later in the course of therapy [32].
Endocrine modulation of the neurotoxicity of gp120: implications for AIDS-related dementia complex. Brooke, S., Chan, R., Howard, S., Sapolsky, R. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
Human immunodeficiency virus infection, inducible nitric oxide synthase expression, and microglial activation: pathogenetic relationship to the acquired immunodeficiency syndrome dementia complex. Rostasy, K., Monti, L., Yiannoutsos, C., Kneissl, M., Bell, J., Kemper, T.L., Hedreen, J.C., Navia, B.A. Ann. Neurol. (1999) [Pubmed]
Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Heyes, M.P., Brew, B.J., Martin, A., Price, R.W., Salazar, A.M., Sidtis, J.J., Yergey, J.A., Mouradian, M.M., Sadler, A.E., Keilp, J. Ann. Neurol. (1991) [Pubmed]
Increased peroxynitrite activity in AIDS dementia complex: implications for the neuropathogenesis of HIV-1 infection. Boven, L.A., Gomes, L., Hery, C., Gray, F., Verhoef, J., Portegies, P., Tardieu, M., Nottet, H.S. J. Immunol. (1999) [Pubmed]
Glioblastoma, transforming growth factor-beta, and Candida meningitis: a potential link. Peterson, P.K., Chao, C.C., Hu, S., Thielen, K., Shaskan, E.G. Am. J. Med. (1992) [Pubmed]
Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Chang, L., Ernst, T., Leonido-Yee, M., Witt, M., Speck, O., Walot, I., Miller, E.N. Neurology (1999) [Pubmed]
A follow-up study of neuropsychological functioning in AIDS-patients. Prognostic significance and effect of zidovudine therapy. Karlsen, N.R., Reinvang, I., Frøland, S.S. Acta neurologica Scandinavica. (1995) [Pubmed]
Serum antioxidant capacity in neurological, psychiatric, renal diseases and cardiomyopathy. Sofic, E., Rustembegovic, A., Kroyer, G., Cao, G. Journal of neural transmission (Vienna, Austria : 1996) (2002) [Pubmed]
Slowed synthesis of DNA and methionine is a pathogenetic mechanism common to dementia in Down's syndrome, AIDS and Alzheimer's disease? Regland, B., Gottfries, C.G. Med. Hypotheses (1992) [Pubmed]
Functional interaction and partial homology between human immunodeficiency virus and neuroleukin. Lee, M.R., Ho, D.D., Gurney, M.E. Science (1987) [Pubmed]
Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Foudraine, N.A., Hoetelmans, R.M., Lange, J.M., de Wolf, F., van Benthem, B.H., Maas, J.J., Keet, I.P., Portegies, P. Lancet (1998) [Pubmed]
AIDS dementia complex and didanosine. Portegies, P., Enting, R.H., de Jong, M.D., Danner, S.A., Reiss, P., Goudsmit, J., Lange, J.M. Lancet (1994) [Pubmed]
Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Haughey, N.J., Cutler, R.G., Tamara, A., McArthur, J.C., Vargas, D.L., Pardo, C.A., Turchan, J., Nath, A., Mattson, M.P. Ann. Neurol. (2004) [Pubmed]
Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Brew, B.J., Bhalla, R.B., Paul, M., Gallardo, H., McArthur, J.C., Schwartz, M.K., Price, R.W. Ann. Neurol. (1990) [Pubmed]
Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. Ehrenreich, H., Rieckmann, P., Sinowatz, F., Weih, K.A., Arthur, L.O., Goebel, F.D., Burd, P.R., Coligan, J.E., Clouse, K.A. J. Immunol. (1993) [Pubmed]
Pilot study of the efficacy of atevirdine in the treatment of AIDS dementia complex. Brew, B.J., Dunbar, N., Druett, J.A., Freund, J., Ward, P. AIDS (1996) [Pubmed]
Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Hriso, E., Kuhn, T., Masdeu, J.C., Grundman, M. The American journal of psychiatry. (1991) [Pubmed]
Nitric oxide synthase expression and apoptotic cell death in brains of AIDS and AIDS dementia patients. Vincent, V.A., De Groot, C.J., Lucassen, P.J., Portegies, P., Troost, D., Tilders, F.J., Van Dam, A.M. AIDS (1999) [Pubmed]
Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues. Saito, Y., Sharer, L.R., Epstein, L.G., Michaels, J., Mintz, M., Louder, M., Golding, K., Cvetkovich, T.A., Blumberg, B.M. Neurology (1994) [Pubmed]
Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex. van Rij, R.P., Portegies, P., Hallaby, T., Lange, J.M., Visser, J., de Roda Husman, A.M., van 't Wout, A.B., Schuitemaker, H. J. Infect. Dis. (1999) [Pubmed]
NFkappaB activation, TNF-alpha expression, and apoptosis in the AIDS-Dementia-Complex. Rostasy, K., Monti, L., Yiannoutsos, C., Wu, J., Bell, J., Hedreen, J., Navia, B.A. J. Neurovirol. (2000) [Pubmed]
Quinolinic acid production is related to macrophage tropic isolates of HIV-1. Brew, B.J., Corbeil, J., Pemberton, L., Evans, L., Saito, K., Penny, R., Cooper, D.A., Heyes, M.P. J. Neurovirol. (1995) [Pubmed]
Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. Kerr, S.J., Armati, P.J., Guillemin, G.J., Brew, B.J. AIDS (1998) [Pubmed]
A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysis. Lee, P.L., Yiannoutsos, C.T., Ernst, T., Chang, L., Marra, C.M., Jarvik, J.G., Richards, T.L., Kwok, E.W., Kolson, D.L., Simpson, D., Tang, C.Y., Schifitto, G., Ketonen, L.M., Meyerhoff, D.J., Lenkinski, R.E., Gonzalez, R.G., Navia, B.A. Journal of magnetic resonance imaging : JMRI. (2003) [Pubmed]
Evaluation of cerebrospinal fluid uPA, PAI-1, and soluble uPAR levels in HIV-infected patients. Sporer, B., Koedel, U., Popp, B., Paul, R., Pfister, H.W. J. Neuroimmunol. (2005) [Pubmed]
SDF-1alpha is expressed in astrocytes and neurons in the AIDS dementia complex: an in vivo and in vitro study. Rostasy, K., Egles, C., Chauhan, A., Kneissl, M., Bahrani, P., Yiannoutsos, C., Hunter, D.D., Nath, A., Hedreen, J.C., Navia, B.A. J. Neuropathol. Exp. Neurol. (2003) [Pubmed]
Overexpression of nerve growth factor and basic fibroblast growth factor in AIDS dementia complex. Boven, L.A., Middel, J., Portegies, P., Verhoef, J., Jansen, G.H., Nottet, H.S. J. Neuroimmunol. (1999) [Pubmed]
Distinct expressions of three cytokines by IL-1-stimulated astrocytes in vitro and in AIDS brain. Vitkovic, L., Chatham, J.J., da Cunha, A. Brain Behav. Immun. (1995) [Pubmed]
Intrathecal synthesis of anti-myelin basic protein IgG in HIV-1+ patients. Maimone, D., Annunziata, P., Cioni, C., Leonardi, A., Guazzi, G.C. Acta neurologica Scandinavica. (1994) [Pubmed]
Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Sidtis, J.J., Gatsonis, C., Price, R.W., Singer, E.J., Collier, A.C., Richman, D.D., Hirsch, M.S., Schaerf, F.W., Fischl, M.A., Kieburtz, K. Ann. Neurol. (1993) [Pubmed]
Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: A proton magnetic resonance spectroscopic study. Tracey, I., Carr, C.A., Guimaraes, A.R., Worth, J.L., Navia, B.A., González, R.G. Neurology (1996) [Pubmed]
Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study. Brunetti, A., Berg, G., Di Chiro, G., Cohen, R.M., Yarchoan, R., Pizzo, P.A., Broder, S., Eddy, J., Fulham, M.J., Finn, R.D. J. Nucl. Med. (1989) [Pubmed]